TY - JOUR AU - Stanojevic, S. AU - Moores, G. AU - Gershon, A. S. AU - Bateman, E. D. AU - Cruz, A. A. AU - Boulet, L. -. P. PY - 2012 DA - 2012// TI - Global asthma prevalence in adults: findings from the cross-sectional world health survey JO - BMC Public Health VL - 12 UR - https://doi.org/10.1186/1471-2458-12-204 DO - 10.1186/1471-2458-12-204 ID - Stanojevic2012 ER - TY - JOUR AU - Chung, K. F. AU - Wenzel, S. E. AU - Brozek, J. L. AU - Bush, A. AU - Castro, M. AU - Sterk, P. J. PY - 2014 DA - 2014// TI - International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma JO - Eur Respir J VL - 43 UR - https://doi.org/10.1183/09031936.00202013 DO - 10.1183/09031936.00202013 ID - Chung2014 ER - TY - JOUR AU - Hekking, P. -. P. W. AU - Wener, R. R. AU - Amelink, M. AU - Zwinderman, A. H. AU - Bouvy, M. L. AU - Bel, E. H. PY - 2015 DA - 2015// TI - The prevalence of severe refractory asthma JO - J Allergy Clin Immunol VL - 135 UR - https://doi.org/10.1016/j.jaci.2014.08.042 DO - 10.1016/j.jaci.2014.08.042 ID - Hekking2015 ER - TY - JOUR AU - Braman, S. S. PY - 2006 DA - 2006// TI - The global burden of asthma JO - Chest VL - 130 UR - https://doi.org/10.1378/chest.130.1_suppl.4S DO - 10.1378/chest.130.1_suppl.4S ID - Braman2006 ER - TY - JOUR AU - Hyland, M. E. AU - Whalley, B. AU - Jones, R. C. AU - Masoli, M. PY - 2015 DA - 2015// TI - A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales JO - Qual Life Res VL - 24 UR - https://doi.org/10.1007/s11136-014-0801-x DO - 10.1007/s11136-014-0801-x ID - Hyland2015 ER - TY - JOUR AU - Israel, E. AU - Reddel, H. K. PY - 2017 DA - 2017// TI - Severe and difficult-to-treat asthma in adults JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMra1608969 DO - 10.1056/NEJMra1608969 ID - Israel2017 ER - TY - JOUR AU - Bel, E. H. AU - Wenzel, S. E. AU - Thompson, P. J. AU - Prazma, C. M. AU - Keene, O. N. AU - Yancey, S. W. PY - 2014 DA - 2014// TI - Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1403291 DO - 10.1056/NEJMoa1403291 ID - Bel2014 ER - TY - JOUR AU - Pavord, I. D. AU - Korn, S. AU - Howarth, P. AU - Bleecker, E. R. AU - Buhl, R. AU - Keene, O. N. PY - 2012 DA - 2012// TI - Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial JO - Lancet VL - 380 UR - https://doi.org/10.1016/S0140-6736(12)60988-X DO - 10.1016/S0140-6736(12)60988-X ID - Pavord2012 ER - TY - JOUR AU - Ortega, H. G. AU - Liu, M. C. AU - Pavord, I. D. AU - Brusselle, G. G. AU - FitzGerald, J. M. AU - Chetta, A. PY - 2014 DA - 2014// TI - Mepolizumab treatment in patients with severe eosinophilic asthma JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1403290 DO - 10.1056/NEJMoa1403290 ID - Ortega2014 ER - TY - JOUR AU - Castro, M. AU - Zangrilli, J. AU - Wechsler, M. E. AU - Bateman, E. D. AU - Brusselle, G. G. AU - Bardin, P. PY - 2015 DA - 2015// TI - Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials JO - Lancet Respir Med VL - 3 UR - https://doi.org/10.1016/S2213-2600(15)00042-9 DO - 10.1016/S2213-2600(15)00042-9 ID - Castro2015 ER - TY - JOUR AU - Nair, P. AU - Wenzel, S. AU - Rabe, K. F. AU - Bourdin, A. AU - Lugogo, N. L. AU - Kuna, P. PY - 2017 DA - 2017// TI - Oral glucocorticoid-sparing effect of Benralizumab in severe asthma JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1703501 DO - 10.1056/NEJMoa1703501 ID - Nair2017 ER - TY - JOUR AU - Chupp, G. L. AU - Bradford, E. S. AU - Albers, F. C. AU - Bratton, D. J. AU - Wang-Jairaj, J. AU - Nelsen, L. M. PY - 2017 DA - 2017// TI - Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial JO - Lancet Respir Med VL - 5 UR - https://doi.org/10.1016/S2213-2600(17)30125-X DO - 10.1016/S2213-2600(17)30125-X ID - Chupp2017 ER - TY - JOUR AU - FitzGerald, J. M. AU - Bleecker, E. R. AU - Nair, P. AU - Korn, S. AU - Ohta, K. AU - Lommatzsch, M. PY - 2016 DA - 2016// TI - Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial JO - Lancet VL - 388 UR - https://doi.org/10.1016/S0140-6736(16)31322-8 DO - 10.1016/S0140-6736(16)31322-8 ID - FitzGerald2016 ER - TY - JOUR AU - Ortega, H. G. AU - Yancey, S. W. AU - Mayer, B. AU - Gunsoy, N. B. AU - Keene, O. N. AU - Bleecker, E. R. PY - 2016 DA - 2016// TI - Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies JO - Lancet Respir Med VL - 4 UR - https://doi.org/10.1016/S2213-2600(16)30031-5 DO - 10.1016/S2213-2600(16)30031-5 ID - Ortega2016 ER - TY - JOUR AU - Yancey, S. W. AU - Keene, O. N. AU - Albers, F. C. AU - Ortega, H. AU - Bates, S. AU - Bleecker, E. R. AU - Pavord, I. PY - 2017 DA - 2017// TI - Biomarkers for severe eosinophilic asthma JO - J Allergy Clin Immunol VL - 140 UR - https://doi.org/10.1016/j.jaci.2017.10.005 DO - 10.1016/j.jaci.2017.10.005 ID - Yancey2017 ER - TY - JOUR AU - Woodruff, P. G. AU - Modrek, B. AU - Choy, D. F. AU - Jia, G. AU - Abbas, A. R. AU - Ellwanger, A. PY - 2009 DA - 2009// TI - T-helper type 2-driven inflammation defines major subphenotypes of asthma JO - Am J Respir Crit Care Med VL - 180 UR - https://doi.org/10.1164/rccm.200903-0392OC DO - 10.1164/rccm.200903-0392OC ID - Woodruff2009 ER - TY - STD TI - National Institute for Health and Care Excellence (NICE). Mepolizumab for treating severe refractory eosinophilic asthma. 25.01.2017. https://www.nice.org.uk/guidance/ta431 [Assessed 25 Jan 2017]. UR - https://www.nice.org.uk/guidance/ta431 ID - ref17 ER - TY - STD TI - Hyland ME, Jones RC, Lanario JW, Masoli M. The construction and validation of the severe asthma questionnaire (SAQ). Eur Respir J. 2018; https://doi.org/10.1183/13993003.00618-2018. ID - ref18 ER - TY - JOUR AU - Farne, H. A. AU - Wilson, A. AU - Powell, C. AU - Bax, L. AU - Milan, S. J. PY - 2017 DA - 2017// TI - Anti-IL5 therapies for asthma JO - Cochrane Database Syst Rev VL - 9 UR - https://doi.org/10.1002/14651858.CD010834.pub3 DO - 10.1002/14651858.CD010834.pub3 ID - Farne2017 ER - TY - JOUR AU - Quanjer, P. H. AU - Stanojevic, S. AU - Cole, T. J. AU - Baur, X. AU - Hall, G. L. AU - Culver, B. H. PY - 2012 DA - 2012// TI - Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations JO - Eur Respir J VL - 40 UR - https://doi.org/10.1183/09031936.00080312 DO - 10.1183/09031936.00080312 ID - Quanjer2012 ER - TY - STD TI - Hancox RJ, Pavord ID, Sears MR. Associations between blood eosinophils and decline in lung function among adults with and without asthma. Eur Respir J. 2018; https://doi.org/10.1183/13993003.02536-2017. ID - ref21 ER - TY - JOUR AU - Mukherjee, M. AU - Aleman Paramo, F. AU - Kjarsgaard, M. AU - Salter, B. AU - Nair, G. AU - LaVigne, N. PY - 2018 DA - 2018// TI - Weight-adjusted intravenous Reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous Mepolizumab JO - Am J Respir Crit Care Med VL - 197 UR - https://doi.org/10.1164/rccm.201707-1323OC DO - 10.1164/rccm.201707-1323OC ID - Mukherjee2018 ER - TY - JOUR AU - Ortega, H. AU - Li, H. AU - Suruki, R. AU - Albers, F. AU - Gordon, D. AU - Yancey, S. PY - 2014 DA - 2014// TI - Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma JO - Ann Am Thorac Soc. VL - 11 UR - https://doi.org/10.1513/AnnalsATS.201312-454OC DO - 10.1513/AnnalsATS.201312-454OC ID - Ortega2014 ER - TY - JOUR AU - Pickard, A. S. AU - Wilke, C. AU - Jung, E. AU - Patel, S. AU - Stavem, K. AU - Lee, T. A. PY - 2008 DA - 2008// TI - Use of a preference-based measure of health (EQ-5D) in COPD and asthma JO - Respir Med VL - 102 UR - https://doi.org/10.1016/j.rmed.2007.11.016 DO - 10.1016/j.rmed.2007.11.016 ID - Pickard2008 ER - TY - STD TI - EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208. ID - ref25 ER - TY - JOUR AU - Korn, S. AU - Both, J. AU - Jung, M. AU - Hübner, M. AU - Taube, C. AU - Buhl, R. PY - 2011 DA - 2011// TI - Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria JO - Ann Allergy Asthma Immunol VL - 107 UR - https://doi.org/10.1016/j.anai.2011.09.001 DO - 10.1016/j.anai.2011.09.001 ID - Korn2011 ER - TY - JOUR AU - Fajt, M. L. AU - Wenzel, S. E. PY - 2017 DA - 2017// TI - Development of new therapies for severe asthma JO - Allergy Asthma Immunol Res VL - 9 UR - https://doi.org/10.4168/aair.2017.9.1.3 DO - 10.4168/aair.2017.9.1.3 ID - Fajt2017 ER - TY - JOUR AU - Gerhardsson de verdier, M. AU - Gustafson, P. AU - McCrae, C. AU - Edsbäcker, S. AU - Johnston, N. PY - 2017 DA - 2017// TI - Seasonal and geographic variations in the incidence of asthma exacerbations in the United States JO - J Asthma VL - 54 UR - https://doi.org/10.1080/02770903.2016.1277538 DO - 10.1080/02770903.2016.1277538 ID - Gerhardsson de verdier2017 ER - TY - JOUR AU - Miller, M. K. AU - Lee, J. H. AU - Miller, D. P. AU - Wenzel, S. E. PY - 2007 DA - 2007// TI - Recent asthma exacerbations: a key predictor of future exacerbations JO - Respir Med VL - 101 UR - https://doi.org/10.1016/j.rmed.2006.07.005 DO - 10.1016/j.rmed.2006.07.005 ID - Miller2007 ER - TY - JOUR AU - Sullivan, P. W. AU - Ghushchyan, V. H. AU - Globe, G. AU - Schatz, M. PY - 2018 DA - 2018// TI - Oral corticosteroid exposure and adverse effects in asthmatic patients JO - J Allergy Clin Immunol VL - 141 UR - https://doi.org/10.1016/j.jaci.2017.04.009 DO - 10.1016/j.jaci.2017.04.009 ID - Sullivan2018 ER - TY - STD TI - Luskin AT, Chipps BE, Rasouliyan L, Miller DP, Haselkorn T, Dorenbaum A. Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol Pract 2014;2:544–52.e1–2. https://doi.org/10.1016/j.jaip.2014.02.011. ID - ref31 ER - TY - STD TI - Stein ML, Villanueva JM, Buckmeier BK, Yamada Y, Filipovich AH, Assa'ad AH, Rothenberg ME. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol. 2008;121:1473–83, 1483.e1–4. https://doi.org/10.1016/j.jaci.2008.02.033. ID - ref32 ER - TY - JOUR AU - Simpson, J. L. AU - Scott, R. AU - Boyle, M. J. AU - Gibson, P. G. PY - 2006 DA - 2006// TI - Inflammatory subtypes in asthma: assessment and identification using induced sputum JO - Respirology VL - 11 UR - https://doi.org/10.1111/j.1440-1843.2006.00784.x DO - 10.1111/j.1440-1843.2006.00784.x ID - Simpson2006 ER - TY - STD TI - Moore WC, Hastie AT, Li X, Li H, Busse WW, Jarjour NN, et al. Sputum neutrophil counts are associated with more sszsevere asthma phenotypes using cluster analysis. J Allergy Clin Immunol. 2014;133:1557. https://doi.org/10.1016/j.jaci.2013.10.011.63.e5. ID - ref34 ER - TY - JOUR AU - Price, D. B. AU - Rigazio, A. AU - Campbell, J. D. AU - Bleecker, E. R. AU - Corrigan, C. J. AU - Thomas, M. PY - 2015 DA - 2015// TI - Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study JO - Lancet Respir Med VL - 3 UR - https://doi.org/10.1016/S2213-2600(15)00367-7 DO - 10.1016/S2213-2600(15)00367-7 ID - Price2015 ER - TY - JOUR AU - FitzGerald, J. M. AU - Bleecker, E. R. AU - Menzies-Gow, A. AU - Zangrilli, J. G. AU - Hirsch, I. AU - Metcalfe, P. PY - 2018 DA - 2018// TI - Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies JO - Lancet Respir Med VL - 6 UR - https://doi.org/10.1016/S2213-2600(17)30344-2 DO - 10.1016/S2213-2600(17)30344-2 ID - FitzGerald2018 ER - TY - STD TI - Selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis. Lung function testing, 1991:144–1202–18. https://doi.org/10.1164/ajrccm/144.5.1202. ID - ref37 ER - TY - JOUR AU - Poon, A. H. AU - Hamid, Q. PY - 2016 DA - 2016// TI - Severe asthma: have we made progress? JO - Ann Am Thorac Soc VL - 13 UR - https://doi.org/10.1513/AnnalsATS.201508-514MG DO - 10.1513/AnnalsATS.201508-514MG ID - Poon2016 ER - TY - JOUR AU - Haldar, P. PY - 2017 DA - 2017// TI - Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma JO - Biologics VL - 11 UR - https://doi.org/10.2147/BTT.S93954 DO - 10.2147/BTT.S93954 ID - Haldar2017 ER - TY - JOUR AU - Basu, A. AU - Dalal, A. AU - Canonica, G. W. AU - Forshag, M. AU - Yancey, S. W. AU - Nagar, S. AU - Bell, C. F. PY - 2017 DA - 2017// TI - Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype JO - Expert Rev Pharmacoecon Outcomes Res VL - 17 UR - https://doi.org/10.1080/14737167.2017.1298444 DO - 10.1080/14737167.2017.1298444 ID - Basu2017 ER - TY - JOUR AU - Kim, Y. -. J. AU - Prussin, C. AU - Martin, B. AU - Law, M. A. AU - Haverty, T. P. AU - Nutman, T. B. AU - Klion, A. D. PY - 2004 DA - 2004// TI - Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700 JO - J Allergy Clin Immunol VL - 114 UR - https://doi.org/10.1016/j.jaci.2004.08.027 DO - 10.1016/j.jaci.2004.08.027 ID - Kim2004 ER - TY - JOUR AU - Haldar, P. AU - Brightling, C. E. AU - Singapuri, A. AU - Hargadon, B. AU - Gupta, S. AU - Monteiro, W. PY - 2014 DA - 2014// TI - Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis JO - J Allergy Clin Immunol VL - 133 UR - https://doi.org/10.1016/j.jaci.2013.11.026 DO - 10.1016/j.jaci.2013.11.026 ID - Haldar2014 ER -